Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Head Neck. 2021 Oct 25;44(1):177–188. doi: 10.1002/hed.26906

Figure 2. NFX1-91 was not significantly increased in HNSCC or HPV positive HNSCC.

Figure 2.

Using the TSVdb, NFX1-91 expression was quantified in: A. primary tumors of HNSCC (n=520) compared to adjacent normal solid tissue (n=44); B. HPV positive HNSCC (n=39) compared to HPV negative HNSCC (n=80); C. and HPV positive oropharyngeal cancer (OPC) (n=34) compared to HPV negative OPC (n=7). D. NFX1-91 mRNA expression in HPV positive OPCs compared to HPV negative OPCs and at different anatomical cancer sites (mouth floor, buccal mucosa, oral tongue, larynx).